2530. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dose Selection for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Community-Acquired Bacterial Pneumonia (CABP)

Sujata M Bhavnani,Mark E Jones,Leonard R Duncan,Paul G Ambrose,Karine Litherland,Anthony J Rinaldo,Jennifer Smart,Jeffrey P Hammel,Christopher M Rubino,Marc Engelhardt

doi:10.1093/ofid/ofad500.2148

2530. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dose Selection for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Community-Acquired Bacterial Pneumonia (CABP)

Sujata M Bhavnani, Mark E Jones + Show 8 more

Open Access

https://doi.org/10.1093/ofid/ofad500.2148

Copy DOI

Journal: Open forum infectious diseases	Publication Date: Nov 27, 2023
License type: CC BY 4.0

Affiliation: Institute for Clinical Pharmacodynamics (United States), Basilea Pharmaceutica (Switzerland), JMI Laboratories

#Acute Bacterial Skin #Acute Bacterial Skin And Skin Structure Infections + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

2530. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dose Selection for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Community-Acquired Bacterial Pneumonia (CABP)

Full Text